- Home
- ANIX vs CLRB Comparison
ANIX vs CLRB Comparison
Compare ANIX & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANIX | CLRB |
|---|---|---|
| Founded | 1982 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.3M | 12.8M |
| IPO Year | 1987 | N/A |
Fundamental Metrics
Financial Performance| Metric | ANIX | CLRB |
|---|---|---|
| Price | $3.19 | $2.57 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 1 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 448.6K | 62.4K |
| Earning Date | 01-09-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.07 | $2.45 |
| 52 Week High | $5.46 | $20.60 |
Technical Indicators
Market Signals| Indicator | ANIX | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 36.80 | 34.11 |
| Support Level | $3.23 | $2.48 |
| Resistance Level | $3.44 | $3.00 |
| Average True Range (ATR) | 0.38 | 0.28 |
| MACD | -0.10 | -0.08 |
| Stochastic Oscillator | 2.78 | 9.37 |
Price Performance
Historical ComparisonAbout ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.